---
title: "KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281676928.md"
description: "KeyBanc analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$87.31.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Keymed Biosciences, Inc. is a Strong Buy with an average price target of HK$85.48."
datetime: "2026-04-04T05:46:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281676928.md)
  - [en](https://longbridge.com/en/news/281676928.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281676928.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281676928.md) | [繁體中文](https://longbridge.com/zh-HK/news/281676928.md)


# KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)

KeyBanc analyst maintained a Buy rating on Keymed Biosciences, Inc. yesterday and set a price target of HK$87.31.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Currently, the analyst consensus on Keymed Biosciences, Inc. is a Strong Buy with an average price target of HK$85.48.

### Related Stocks

- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md)
- [KEYMED BIO-B (02162.HK)](https://longbridge.com/en/quote/02162.HK.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)

## Related News & Research

- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [Barclays Sticks to Its Buy Rating for UCB SA (0NZT)](https://longbridge.com/en/news/280966907.md)
- [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/en/news/281662341.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/en/news/281644038.md)
- [08:33 ETDrugwatch Investigation Reveals Big Pharma Profits Continue to Outpace Billions in Legal Penalties](https://longbridge.com/en/news/281368752.md)